OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OKYO OKYO Pharma Limited

Closed Mourning Day 01-08 16:00:00 EST

1.29

+0.12

+9.89%

盘后1.34

+0.06+4.28%

19:58 EST

High1.35	Low1.15	Vol1.01M
Open1.20	D1 Closing1.17	Amplitude17.10%
Mkt Cap43.48M	Tradable Cap30.74M	Total Shares33.84M
T/O1.28M	T/O Rate4.22%	Tradable Shares23.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"OKYO","market":"US","secType":"STK","nameCN":"OKYO Pharma Limited","latestPrice":1.285,"timestamp":1736370000000,"preClose":1.1694,"halted":0,"volume":1010022,"hourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.285,"latestTime":"19:58 EST","volume":10840,"amount":14102.7941,"timestamp":1736384293692},"delay":0,"floatShares":23921382,"shares":33836316,"eps":-0.573392,"marketStatus":"Closed Mourning Day","change":0.1156,"latestTime":"01-08 16:00:00 EST","open":1.2,"high":1.35,"low":1.15,"amount":1279627.8794754,"amplitude":0.171028,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.573392,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1736499600000},"marketStatusCode":7,"adr":0,"adrRate":65,"listingDate":1652760000000,"exchange":"NASDAQ","adjPreClose":1.1694,"preHourTrading":{"tag":"盘前","latestPrice":1.2084,"preClose":1.16,"latestTime":"09:29 EST","volume":1414,"amount":1693.6579505999998,"timestamp":1736346566353},"postHourTrading":{"tag":"盘后","latestPrice":1.34,"preClose":1.285,"latestTime":"19:58 EST","volume":10840,"amount":14102.7941,"timestamp":1736384293692},"volumeRatio":49.59840859164402},"requestUrl":"/m/hq/s/OKYO/tweets","defaultTab":"tweets","newsList":[{"id":"2486740860","title":"OKYO Pharma to Highlight Innovations at BTIG Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486740860","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486740860?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:29","pubTimestamp":1732624164,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR (OKYO) has released an update. OKYO Pharma Limited is set to participate in the 4th Annual BTIG Ophthalmology Con...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-highlight-innovations-at-btig-conference?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-to-highlight-innovations-at-btig-conference?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2486079442","title":"OKYO Pharma to Participate at the 4th Annual BTIG Ophthalmology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2486079442","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486079442?lang=en_us&edition=fundamental","pubTime":"2024-11-26 20:00","pubTimestamp":1732622400,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Nov. 26, 2024  -- OKYO Pharma Limited , a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain , a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease , a multi-billion-dollar market, is pleased to announce that its CEO, Gary S. Jacob, Ph.D., will be participating in one on one meetings and a fireside chat at the 4thAnnual Virtual BTIG Ophthalmology Day on Monday, December 2nd, 2024. More than 20 public and private medical technology and biotechnology companies will be participating in BTIG’s event. Panel discussion topics will include exploring the latest developments and trends within ophthalmic medical technologies and therapeutics.About OKYOOKYO Pharma Limited  is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2zdmO84FHYP4OHLkyHh3ig--~B/aD01NjY7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fe3c7931ce0406f6f60fe0bf177e6bb2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2zdmO84FHYP4OHLkyHh3ig--~B/aD01NjY7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fe3c7931ce0406f6f60fe0bf177e6bb2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/okyo-pharma-participate-4th-annual-120000940.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","BK4139","NQmain","TQQQ","SQQQ",".IXIC","PSQ","QLD","QID","OKYO"],"gpt_icon":1},{"id":"2483121371","title":"MUSQ Global Music Industry ETF and OKYO Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2483121371","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483121371?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:00","pubTimestamp":1731679200,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESSWIRE / November 15, 2024 / RedChip Companies will air interviews with MUSQ Global Music Industry ETF  and OKYO Pharma Ltd.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, November 16, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.In an exclusive interview, David Schulhof, Founder and CEO of MUSQ LLC, the company behind the MUSQ Global Music Industry ETF, appears on the RedChip Small Stocks Big Money show on Bloomberg TV to share insight into how the MUSQ ETF provides investors with exposure to the global music ecosystem. Tracking the MUSQ Global Music Industry Index , the ETF includes publicly traded companies with core interests in music streaming, content and distribution, live events, satellite and broadcast radio, and music equipment and technology. The global music industry is projected to grow at a double-digit pace, with Goldman Sachs predicting the industry","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/musq-global-music-industry-etf-140000843.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","FDN","BK4588","AIRI","BK4139","BK4100","BK4590","BK4555","BK4581","BK4144","BK4561","BK4099","BK4187","OKYO","MUSQ","ET","03160","BK4550","TV","TM"],"gpt_icon":0},{"id":"2479270046","title":"OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2479270046","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479270046?lang=en_us&edition=fundamental","pubTime":"2024-10-30 19:00","pubTimestamp":1730286000,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Oct. 30, 2024  -- OKYO Pharma Limited , a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain , a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease , a multi-billion-dollar market, is pleased to announce that it will be presenting at the 10th International Tear Film & Ocular Surface Society Conference in Venice, Italy during October 30 - November 2, 2024. The OKYO management team will be participating in one-on-one meetings to discuss the dry eye disease trial results, and also the recent opening of our Phase 2 trial of OK-101 to treat patients with Neuropathic Corneal Pain at Tufts Medical Center, Boston, Massachusetts, USA.About OK-101OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a mem","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2zdmO84FHYP4OHLkyHh3ig--~B/aD01NjY7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fe3c7931ce0406f6f60fe0bf177e6bb2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2zdmO84FHYP4OHLkyHh3ig--~B/aD01NjY7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fe3c7931ce0406f6f60fe0bf177e6bb2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/okyo-pharma-present-international-tear-110000634.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference","news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OKYO","BK4139"],"gpt_icon":1},{"id":"2477686966","title":"OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2477686966","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477686966?lang=en_us&edition=fundamental","pubTime":"2024-10-24 19:12","pubTimestamp":1729768320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 24, 2024 07:12 ET (11:12 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"gpt_icon":0},{"id":"2477300887","title":"OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2477300887","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477300887?lang=en_us&edition=fundamental","pubTime":"2024-10-23 19:00","pubTimestamp":1729681200,"startTime":"0","endTime":"0","summary":"OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain  in a clinical trial. The Phase 2 trial is designed as a randomized, placebo-controlled, double-masked study to treat 48 NCP patients. LONDON and NEW YORK, Oct. 23, 2024  -- OKYO Pharma Limited , an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat corneal neuropathic pain , an ocular condition associated with pain but without an FDA-approved therapy, is pleased to announce that the first patient has been dosed in the Phase 2 trial of topical ocular OK-101 to treat NCP. The Phase 2 study is designed as a double-masked, randomized, 12-week placebo-controlled trial in NCP patients. A total of 48 patients are planned to enroll for the study, with NCP disease confirmed via confocal microscopy.“We are excited to announce the enrollment of the first patient in our Phase 2 clinical trial of OK-101,” said Dr. Gar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2zdmO84FHYP4OHLkyHh3ig--~B/aD01NjY7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fe3c7931ce0406f6f60fe0bf177e6bb2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2zdmO84FHYP4OHLkyHh3ig--~B/aD01NjY7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fe3c7931ce0406f6f60fe0bf177e6bb2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/okyo-pharma-announces-first-patient-110000838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2476142165","title":"OKYO Pharma Begins Key Phase 2 Trial for Eye Pain Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2476142165","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476142165?lang=en_us&edition=fundamental","pubTime":"2024-10-17 19:27","pubTimestamp":1729164450,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR  has released an update.OKYO Pharma Limited has commenced a Phase 2 clinical trial for its drug OK-101, targeting neuropathic corneal pain , a rare and debilitating eye condition lacking FDA-approved treatments. The trial aims to enroll 48 participants and follows promising results from a previous trial where OK-101 showed significant improvements in ocular pain associated with dry eye disease. This development marks a crucial step for OKYO as it continues to advance its innovative therapies for eye conditions in the pharmaceutical market.For further insights into OKYO stock, check out TipRanks’ Stock Analysis page.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6MInUe1T4fs5TaG11G3efw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/87b9ff78d08b9d461f46ab67f57ff730","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6MInUe1T4fs5TaG11G3efw--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/87b9ff78d08b9d461f46ab67f57ff730"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/okyo-pharma-begins-key-phase-112730608.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/okyo-pharma-begins-key-phase-112730608.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2476929688","title":"OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2476929688","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476929688?lang=en_us&edition=fundamental","pubTime":"2024-10-17 02:49","pubTimestamp":1729104540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 16, 2024 14:49 ET (18:49 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"gpt_icon":0},{"id":"2475965120","title":"OKYO Pharma Announces Start of Phase 2 Clinical Trial to Treat Patients with Neuropathic Corneal Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2475965120","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475965120?lang=en_us&edition=fundamental","pubTime":"2024-10-16 19:00","pubTimestamp":1729076400,"startTime":"0","endTime":"0","summary":"Neuropathic corneal pain (NCP) is listed in the National Organization for Rare Disorders (NORD) as an orphan diseaseOKYO is the first company to have an IND application granted by the FDA for NCP The ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/16/2963919/0/en/OKYO-Pharma-Announces-Start-of-Phase-2-Clinical-Trial-to-Treat-Patients-with-Neuropathic-Corneal-Pain.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO","BK4139","NORD"],"gpt_icon":0},{"id":"2466431827","title":"OKYO Pharma Chairman Boosts Stake, Advances Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=2466431827","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466431827?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:28","pubTimestamp":1725967687,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR (OKYO) has released an update. OKYO Pharma Limited has announced that its Executive Chairman, Gabriele Cerrone, t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-chairman-boosts-stake-advances-trials-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-chairman-boosts-stake-advances-trials-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2466435627","title":"OKYO Pharma Announces Chairman Acquires Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2466435627","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466435627?lang=en_us&edition=fundamental","pubTime":"2024-09-10 19:00","pubTimestamp":1725966000,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Sept.  10, 2024  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/10/2943513/0/en/OKYO-Pharma-Announces-Chairman-Acquires-Shares.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","BK4139","NQmain","TQQQ","SQQQ",".IXIC","PSQ","QLD","QID","OKYO"],"gpt_icon":1},{"id":"2465541827","title":"OKYO Pharma Announces Chairman Acquires Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2465541827","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2465541827?lang=en_us&edition=fundamental","pubTime":"2024-09-05 19:00","pubTimestamp":1725534000,"startTime":"0","endTime":"0","summary":"About OK-101OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing efficacy signals in mouse models of dry eye disease and corneal neuropathic pain , respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 recently showed statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-blind, placebo-controlled trial of OK-101 to treat DED.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2zdmO84FHYP4OHLkyHh3ig--~B/aD01NjY7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fe3c7931ce0406f6f60fe0bf177e6bb2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2zdmO84FHYP4OHLkyHh3ig--~B/aD01NjY7dz0xNTAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/fe3c7931ce0406f6f60fe0bf177e6bb2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/okyo-pharma-announces-chairman-acquires-110000462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OKYO","MNQmain","QLD","NQmain","TQQQ","QID","PSQ","SQQQ",".IXIC","BK4139"],"gpt_icon":1},{"id":"2462002115","title":"OKYO Pharma Price Target Maintained With a $7.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2462002115","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462002115?lang=en_us&edition=fundamental","pubTime":"2024-08-28 00:49","pubTimestamp":1724777340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OKYO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 27, 2024 12:49 ET (16:49 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKYO"],"gpt_icon":0},{"id":"2462180111","title":"Buy Rating on OKYO Pharma: U.S. Patent and Strong Trial Results for OK-101 Boosts Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2462180111","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462180111?lang=en_us&edition=fundamental","pubTime":"2024-08-27 23:55","pubTimestamp":1724774135,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR (OKYO – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-on-okyo-pharma-u-s-patent-and-strong-trial-results-for-ok-101-boosts-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-on-okyo-pharma-u-s-patent-and-strong-trial-results-for-ok-101-boosts-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OKYO"],"gpt_icon":0},{"id":"2462199263","title":"Okyo Pharma Gets US Patent for Potential Treatment of Dry Eye Disease Symptoms","url":"https://stock-news.laohu8.com/highlight/detail?id=2462199263","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462199263?lang=en_us&edition=fundamental","pubTime":"2024-08-27 22:23","pubTimestamp":1724768585,"startTime":"0","endTime":"0","summary":"Okyo Pharma  said Tuesday it received a US patent for OK-101 to treat symptoms of dry eye disease.The patent, issued Aug. 6, covers the use of OK-101 to treat irritated, burning eyes and blurred vision in patients with dry eye disease, according to the company.Price: 0.94, Change: -0.01, Percent Change: -1.34","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OKYO","BK4139"],"gpt_icon":0},{"id":"2462165377","title":"OKYO Pharma Secures U.S. Patent for DED Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2462165377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462165377?lang=en_us&edition=fundamental","pubTime":"2024-08-27 19:28","pubTimestamp":1724758088,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR (OKYO) has released an update. OKYO Pharma Limited has announced the grant of a critical U.S. patent for OK-101, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-secures-u-s-patent-for-ded-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-secures-u-s-patent-for-ded-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2462492168","title":"OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2462492168","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462492168?lang=en_us&edition=fundamental","pubTime":"2024-08-27 19:00","pubTimestamp":1724756400,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Aug.  27, 2024  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/27/2936102/0/en/OKYO-Pharma-Granted-U-S-Patent-Covering-OK-101-s-Potential-for-Treating-Symptoms-of-Dry-Eye-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","BK4139","NQmain","TQQQ","SQQQ",".IXIC","PSQ","QLD","QID","OKYO"],"gpt_icon":1},{"id":"2461059179","title":"OKYO Pharma Advances in Ocular Disease Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2461059179","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461059179?lang=en_us&edition=fundamental","pubTime":"2024-08-23 21:27","pubTimestamp":1724419632,"startTime":"0","endTime":"0","summary":"OKYO Pharma Limited Sponsored ADR (OKYO) has released an update. OKYO Pharma Limited, a biopharmaceutical company, is making strides in developing ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-advances-in-ocular-disease-therapies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/okyo-pharma-advances-in-ocular-disease-therapies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","OKYO"],"gpt_icon":0},{"id":"2461995935","title":"OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2461995935","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461995935?lang=en_us&edition=fundamental","pubTime":"2024-08-23 21:00","pubTimestamp":1724418000,"startTime":"0","endTime":"0","summary":"ORLANDO, FL / ACCESSWIRE / August 23, 2024 / RedChip Companies will air interviews with OKYO Pharma Ltd.  and SolarMax Technology, Inc.  on the RedChip Small Stocks, Big Money show, a sponsored program on Bloomberg TV, this Saturday, August 24, at 7 p.m. Eastern Time . Bloomberg TV is available in an estimated 73 million homes across the U.S.OKYO Pharma Limited  is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of DED and NCP, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. In addition to the recently completed Phase 2 DED trial, OKYO also has plans underway for the opening of a Phase 2 trial for OK-101 to treat NCP in patients with this debilitating","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_CGqlr_T72W08fVAOQ9fAw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/e0cfc5cb7f676adb9179054efe7f38b8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/okyo-pharma-solarmax-technology-interviews-130000084.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QLD","TV","SMXT","TQQQ","BK4581","AIRI","BK4139","ET","SQQQ","MNQmain","QQQ","OKYO","BK4561","BK4100","QID",".IXIC","TM","BK4588","BK4590","BK4096","PSQ","03160","BK4099","BK4585","BK4187","BK4144","NQmain","BK4555"],"gpt_icon":0},{"id":"2461596496","title":"OKYO Pharma CEO Interview to Air on Bloomberg TV","url":"https://stock-news.laohu8.com/highlight/detail?id=2461596496","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2461596496?lang=en_us&edition=fundamental","pubTime":"2024-08-23 21:00","pubTimestamp":1724418000,"startTime":"0","endTime":"0","summary":"LONDON and NEW YORK, Aug.  23, 2024  (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of infl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/08/23/2934916/0/en/OKYO-Pharma-CEO-Interview-to-Air-on-Bloomberg-TV.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4590","TQQQ","TV","ET","OKYO","BK4585","AIRI","MNQmain","BK4139","BK4561","BK4187","NQmain","QID","BK4100","PSQ","BK4588","QQQ","QLD",".IXIC","SQQQ","BK4144"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.okyopharma.com","stockEarnings":[{"period":"1week","weight":0.1175},{"period":"1month","weight":0.2009},{"period":"3month","weight":0.285},{"period":"6month","weight":-0.1918},{"period":"1year","weight":-0.274},{"period":"ytd","weight":0.1175}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":-0.0251},{"period":"3month","weight":0.0232},{"period":"6month","weight":0.0527},{"period":"1year","weight":0.244},{"period":"ytd","weight":0.0058}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease; in phase 1 clinical trial for the treatment of neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201, which is in preclinical trial for the treatment of dry eye disease and neuropathic chronic pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.","exchange":"NASDAQ","name":"OKYO Pharma Limited","nameEN":"OKYO Pharma Limited"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"OKYO Pharma Limited,OKYO,OKYO Pharma Limited股票,OKYO Pharma Limited股票老虎,OKYO Pharma Limited股票老虎国际,OKYO Pharma Limited行情,OKYO Pharma Limited股票行情,OKYO Pharma Limited股价,OKYO Pharma Limited股市,OKYO Pharma Limited股票价格,OKYO Pharma Limited股票交易,OKYO Pharma Limited股票购买,OKYO Pharma Limited股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"OKYO Pharma Limited(OKYO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest OKYO Pharma Limited(OKYO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction